TOKYO, Aug 24 (Reuters) – Takeda Pharmaceutical Co 4502.T has agreed to sell its Japanese consumer healthcare business to U.S. investment fund Blackstone Group BX.N for 242 billion yen ($2.3 billion), Japan’s largest drugmaker said on Monday.
The sale of Takeda Consumer Healthcare Company, which makes over-the-counter (OTC) drugs and health products, is expected to close by March 31, subject to regulatory closing conditions, the company said in a statement.
Takeda has been reducing its OTC assets worldwide as it seeks to refocus its business and reduce debt after its $59 billion acquisition of Shire.
($1 = 105.8300 yen)
(Reporting by Chris Gallagher Editing by David Goodman )
(([email protected];))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
